Survey 32 -Questionnaire-Pyloshot-adboardMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File “H. pylori: Beyond the Gut – From Stomach to Systemic Health”- Adboard Questionnaire1. Beyond dyspepsia, which systemic manifestations of H. pylori do you most frequently encounter in practice? Iron-deficiency anemia Vitamin B12 deficiency Atrophic gastritis–related complications Fatigue and nutritional impact Low-grade systemic inflammation2. In patients with unexplained anemia or B12 deficiency, how routinely do you evaluate for H. pylori? As part of routine work-up Only after failure of supplementation On referral from other specialties Rarely—needs more awareness3. What clinical or laboratory clues prompt suspicion of H. pylori in extra-gastric conditions? Refractory anemia Poor response to oral iron/B12 Chronic gastritis on endoscopy Long-standing dyspeptic symptoms Family history of gastric pathology4. How strong is the evidence linking chronic H. pylori infection to atrophic gastritis and future gastric cancer risk—especially in Indian patients? Strong and well-established Moderate but clinically relevant Under-recognized in routine practice Needs more India-specific awareness5. Do you see meaningful improvement in anemia or micronutrient deficiencies after H. pylori eradication? Clear improvement post-eradication Improvement only in selected patients Needs longer follow-up Limited if compliance is poor6. From your clinical perspective, should chronic H. pylori infection be considered a modifiable inflammatory risk factor in patients with cardiometabolic disease? Yes, due to persistent low-grade systemic inflammation Yes, particularly in long-standing or CagA-positive infections Possibly, but only as a contributory (not causal) factor Only relevant in patients with multiple existing risk factors Evidence is suggestive but requires stronger validation7. What are the biggest real-world challenges in achieving successful H. pylori eradication today? Antibiotic resistance Poor patient compliance Adverse effects of therapy Incomplete treatment courses Lack of supportive therapy8. Should H. pylori be viewed as a systemic inflammatory trigger rather than only a gastric pathogen? Yes, due to chronic inflammation Yes, in long-standing infections Emerging evidence supports this Requires mindset shift in practice9. What unmet need still exists in current H. pylori management strategies? Higher eradication rates Better patient adherence Reduced adverse effects More evidence-based adjunctive options Simplified regimens10. What is your perspective on using novel non-antibiotic adjuncts alongside standard eradication therapy for H. pylori? Helpful in improving eradication outcomes Primarily useful for tolerability and compliance Beneficial in resistant or recurrent cases Still evolving but clinically promising11. What key advantages have you observed with L. reuteri DSM 17648 when used alongside standard eradication therapy? Reduction in antibiotic-related side effects Improved treatment completion Better patient comfort Lower H. pylori load Improved eradication confidence12. Do you believe adjunctive therapies like L. reuteri DSM 17648 represent the future of more patient-friendly and effective H. pylori management? Yes, especially with rising resistance Yes, for compliance-driven success Yes, in long-term disease prevention Needs wider awareness and guideline support I have read and agree to the Terms and Conditions .Submit Form